Emergent BioSolutions (NYSE:EBS) Trading Down 7.1% – Time to Sell?

Shares of Emergent BioSolutions Inc. (NYSE:EBS) dropped 7.1% during mid-day trading on Tuesday . The stock traded as low as $11.04 and last traded at $11.12. Approximately 422,386 shares were traded during trading, a decline of 88% from the average daily volume of 3,386,532 shares. The stock had previously closed at $11.97.

Wall Street Analysts Forecast Growth

EBS has been the topic of several analyst reports. Rodman & Renshaw restated a “buy” rating and set a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark raised their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Trading Down 9.0 %

The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 0.54. The company has a market cap of $590.06 million, a price-to-earnings ratio of -2.63 and a beta of 1.57. The business has a 50 day simple moving average of $8.50 and a 200 day simple moving average of $7.89.

Institutional Investors Weigh In On Emergent BioSolutions

Several large investors have recently modified their holdings of EBS. SeaCrest Wealth Management LLC grew its holdings in shares of Emergent BioSolutions by 3.2% during the third quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company’s stock worth $991,000 after buying an additional 3,705 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Emergent BioSolutions by 22.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 4,409 shares during the last quarter. CWM LLC lifted its position in shares of Emergent BioSolutions by 32,706.7% in the second quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 4,906 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Emergent BioSolutions in the second quarter valued at approximately $41,000. Finally, Verus Capital Partners LLC acquired a new stake in shares of Emergent BioSolutions in the second quarter valued at approximately $68,000. 78.40% of the stock is currently owned by institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.